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Abstract
Background: Streptococcus pneumoniae Neuraminidase A (NanA) is a multi-domain protein anchored to the
bacterial surface. Upstream of the catalytic domain of NanA is a domain that conforms to the sialic acid-recognising
CBM40 family of the CAZY (carbohydrate-active enzymes) database. This domain has been identified to play a
critical role in allowing the bacterium to promote adhesion and invasion of human brain microvascular endothelial
cells, and hence may play a key role in promoting bacterial meningitis. In addition, the CBM40 domain has also
been reported to activate host chemokines and neutrophil recruitment during infection.
Results: Crystal structures of both apo- and holo- forms of the NanA CBM40 domain (residues 121 to 305), have
been determined to 1.8 Å resolution. The domain shares the fold of other CBM40 domains that are associated with
sialidases. When in complex with α2,3- or α2,6-sialyllactose, the domain is shown to interact only with the terminal
sialic acid. Significantly, a deep acidic pocket adjacent to the sialic acid-binding site is identified, which is occupied
by a lysine from a symmetry-related molecule in the crystal. This pocket is adjacent to a region that is predicted to
be involved in protein-protein interactions.
Conclusions: The structural data provide the details of linkage-independent sialyllactose binding by NanA CBM40
and reveal striking surface features that may hold the key to recognition of binding partners on the host cell
surface. The structure also suggests that small molecules or sialic acid analogues could be developed to fill the
acidic pocket and hence provide a new therapeutic avenue against meningitis caused by S. pneumoniae.
Background
Streptococcus pneumoniae is a human pathogen respon-
sible for respiratory tract infections, septicaemia and
meningitis. Several virulence factors contribute to
colonization and early infection processes [1]. Sialidases
from pathogenic bacteria are considered as key virulence
factors, as they remove sialic acid from host cell surface
glycans, unmasking certain receptors to facilitate bacterial
adherence and colonization. All S. pneumoniae clinical
isolates investigated to date possess prominent sialidase
activities. Three sialidases, NanA, NanB and NanC, are
encoded by S. pneumoniae genomes. A study of sialidase
genes in clinical pneumococcal isolates identified nanA,
nanB and nanC to be present in 100 %, 96 % and 51 % of
these strains, respectively [2]. Pneumococcal strains with
knockouts of nanA or nanB, and studied in mouse
models, show that both proteins are essential to S. pneu-
moniae infection of the respiratory tract and sepsis [3].
NanA, specifically, has been shown to play an important
role in host-pneumococcal interactions in the upper
respiratory tract [4, 5], and is involved in biofilm forma-
tion [6]. It has also been shown to desialylate competing
bacteria such as Neisseria meningitidis and Haemophilus
influenzae, potentially giving S. pneumoniae an advantage
in shared bacterial niches [7]. Furthermore, the NanA
from S. pneumoniae has also been shown to promote
inflammation by disrupting sialic acid based recognition of
CD24 by SiglecG in mice (the equivalent of SIGLEC10 in
humans) [8].
From amino acid sequence comparison of bacterial
sialidases, NanA is modular by nature and its domain
organisation is similar to other known bacterial siali-
dases (Fig. 1). The enzyme contains a catalytic domain
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flanked by an N-terminal carbohydrate-binding domain
(CBM) that is downstream of a signal sequence, followed
by a region of predicted disorder. At the C-terminus,
there is a region rich in proline, glycine, threonine and
serine containing a sequence of 20 amino acids repeated
three times contiguously followed by an LPXTG anchor
sequence. Subsequent analysis of multiple pneumococcal
strains showed that the nanA gene is highly diverse,
mainly in truncations in the C-terminal region, but that
the N-terminal CBM and catalytic domain are conserved
[9]. Two studies have reported the importance of NanA
in allowing S. pneumoniae to adhere to and invade the
blood–brain-barrier (BBB), through the use of human
brain microvascular endothelial cells (hBMECs). In par-
ticular the N-terminal CBM domain (described in the
study as a laminin G-like domain) was found to be the
critical determinant of this event [10, 11]. Both of these
studies showed that the catalytic activity of NanA only
played a minor role in the adhesion/invasion event, with
one study showing that the N-terminal CBM was also
involved in the induction of neutrophil chemo-
attractants IL-8, CXCL-1 and CXCL-2 [11].
We recently cloned the N-terminal CBM domain of
NanA (residues 121–305) and carried out a glycan array
screen that showed the domain binds to sialic acid [12],
and as such is a Family 40 CBM as defined in the CAZY
database [13]. We have also engineered multivalent
forms of this domain, designed to adhere with high af-
finity to sialic acid receptors in the respiratory tract, and
have shown that they prevent infection from influenza
viruses in a mouse model. Preliminary analysis of immu-
nomodulators during this influenza study supports the
ability of this domain to stimulate the immune system in
mice, specifically IL-1β, MIP-2 (the mouse homolog of
IL-8), IFN-γ and TNF-α [12].
To date, only the catalytic domain of NanA has been
studied structurally, and is the subject of small molecule
inhibitor studies [14–16]. Here we describe the crystal
structure of the S. pneumoniae NanA CBM40 domain,
hereafter named SpCBM. Crystal structures of SpCBM,
complexed with α2,3-sialyllactose (Neu5Ac-α2,3-Gal-β1,
4-Glc, from here on referred to as 3’SL) and α2,6-sialyll
actose (Neu5Ac-α2,6-Gal-β1,4-Glc, from here on re-
ferred to as 6’SL) are also described. The structure of
SpCBM is compared to other known CBM40 structures
showing that it shares a similar fold. In contrast to the
other CBM40 domains, SpCBM has a deep water-filled
pocket adjacent to the N-acetyl moiety of sialic acid and
surrounded by a positively charged surface. In the crystal
structures, the acidic pocket is partially occupied by a
lysine residue from a symmetry-related molecule. The
structure of SpCBM suggests that it may recognise a sec-
ond receptor that may be responsible for the induction
of chemokines, and the BBB invasion event.
Results
Structure overview
All residues (from Val121 to Ser305) of the expressed
CBM were clearly identifiable in the SpCBM crystal struc-
ture. As shown in Fig. 2, the native structure constitutes a
central β-sandwich (comprising one antiparallel β-sheet
containing five-strands and a second antiparallel β-sheet
containing six-strands), a β-hairpin on one side of the
sandwich, an α-helix present between the β-sheets and a
C-terminal α-helix packing against the β-sandwich. When
compared to other CBM40 structures, SpCBM is structur-
ally homologous to CBM40 modules from C. perfringens
NanJ [PDB ID: 2 V73]; RMSD 1.7 Å for 169 Cα’s [17], S.
pneumoniae NanB [PDB ID: 2VW0]; RMSD 2.0 Å for 170
Cα’s [18], M. decora NanL [PDB ID: 2SLI]; RMSD 2.0 Å
for 176 Cα’s [19], and V. cholerae NanH [PDB ID: 1W0P];
RMSD 3.1 Å for 134 Cα’s [20]. The superposition of
SpCBM with these structurally homologous domains is
shown in Fig. 3.
Ligand binding site
For the complexed structures, both 3’SL and 6’SL were
co-crystallized with SpCBM. There are no significant con-
formational changes between the apo SpCBM structure
Fig. 1 Schematic of the NanA domains
Fig. 2 Overall structure of the SpCBM. Cartoon representation of the
SpCBM in two orientations, coloured in rainbow colours from blue at
the N-terminus to red at the C-terminus
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and the complexed structure, and superimposition of the
apo and holo structures gives an RMSD of 0.48 Å over all
Cα atoms for both 3’SL and 6’SL. Difference electron-
density maps of both 3’SL and 6’SL molecules, in complex
with SpCBM, are clearly defined (Fig. 4), particularly the
sialic acid moiety of each sialoside. In the 3’SL and 6’SL
complexes, the protein structures are highly similar, giving
an RMSD of 0.06 Å for all of the Cα atoms while the sialic
acid moieties of the ligands are completely superimpos-
able. The lactose moieties of the 3’SL and 6’SL, however,
point in opposite directions (Fig. 4a & b). In 3’SL, lactose
does not interact with the protein, although O6 of the glu-
cose moiety interacts with O9 of sialic acid. In 6’SL, glu-
cose O6 interacts with the side chain of Asp180. For both
ligands, the lactose B-factors are significantly higher than
the corresponding sialic acid moiety.
For SpCBM, the residues that are involved in the inter-
action are mainly donated from the concave surface
formed by the β-hairpin and three β-strands (Fig. 4c). As
shown in Fig. 5, the carboxylate group of Neu5Ac forms
a bidentate interaction with Arg274, a common feature
in proteins that bind sialic acid. Arg197 also interacts
with one of the carboxylate oxygens of Neu5Ac. Other
Neu5Ac atoms make additional interactions with
SpCBM: O4 interacts with the side chain of Glu195 as
does the N5 of the acetamido group; the O10 carbonyl
oxygen of the acetamido group interacts with Asn209;
the glycerol O8 hydroxyl oxygen interacts with the imid-
azole nitrogen of Trp280. Phe167 provides a hydrophobic
platform supporting the glycerol carbons (C7 to C9) that
are ~4 Å away, and also forms part of the hydrophobic
pocket accommodating the acetamido methyl group. A
number of water molecules are seen to bridge interac-
tions between Neu5Ac and the protein. Details of the
major interactions between SpCBM and ligand are
listed in Table 1.
Acidic cavity adjacent to sialic acid binding site
A striking feature of the protein is a deep, negatively
charged cavity adjacent to the sialic acid binding site
Fig. 3 Stereo view of the cartoon representation of the superimposition of SpCBM with other CBM40 family members. a SpCBM is shown in
green, NanB-CBM is shown in blue, NanJ-CBM is shown in yellow and NanL-CBM is shown in pink. b Superimposition of SpCBM with NanH-CBM.
NanH-CBM is shown in grey
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(Fig. 6a). This pocket is formed by four residues
(Glu195, Gln203, Asn207 and Asn209), and is occupied
by a lysine from a symmetry-related molecule (Fig. 6b).
Interestingly, a region immediately adjacent to this
pocket and to the sialic acid binding site is highlighted
by the results of the meta-PPISP server as a likely pro-
tein interaction site (Fig. 7). No other protein binding
sites on SpCBM are predicted, and no such sites are pre-
dicted on the CBMs of NanB, NanL or NanH. NanJ
CBM has a low-scoring patch in a region that overlaps
with the corresponding patch on SpCBM.
Kinetics and binding affinity of SpCBM interaction with
3’SL
A sensogram showing the association and dissociation of
SpCBM binding to 3’SL is shown in Fig. 8a. The kinetic
parameters for the interaction based on global fitting of
raw data using a 1:1 (Langmuir) binding model gave a
Fig. 4 3’SL and 6’SL co-complexed with SpCBM. a Stereo view of Fo-Fc map of 3’SL co-complex contoured at 2.5σ level. b Stereo view of Fo-Fc
map of 6’SL co-complex contoured at 2.5σ level. c Stereo view of 3’SL (shown in spheres) bound to the SpCBM substrate-binding site
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KD value of 1.8 ± 0.13 μM and R
2 of 0.99 (data not
shown). As equilibrium was also observed with the dif-
ferent SpCBM concentrations, a KD value of 1.8 ±
0.12 μM was determined from steady state binding by
plotting the response at equilibrium against SpCBM
concentration (Fig. 8b).
Discussion
CBM40 domains have been described structurally for
other sialidases from Vibrio cholerae NanH [20], Clos-
tridium perfringens NanJ [17], S. pneumoniae NanB [18]
and Macrobdella decora NanL [19], with sialic acid
binding only visualised in the first two. The CBM40
domains all share a common lectin β-sandwich fold with
two antiparallel β-sheets containing five and six strands,
in addition to other secondary structural elements. The
sialic acid binding site is located in the concave surface
of the five-stranded sheet, although the nature of the
ligand interactions in the sialic acid complexes with V.
cholerae NanH and C. perfringens NanJ are quite differ-
ent and the binding sites are at different locations on the
concave surface.
In their description of C. perfringens NanJ, Boraston
et al. pointed out that there appear to be two subfamilies
within the CBM40 family, one typified by C. perfringens
NanJ and the other by V. cholerae NanH [17]. The struc-
ture of SpCBM confirms that it belongs to the subfamily
that includes C. perfringens NanJ and also S. pneumoniae
NanB and M. decora NanL CBMs.
Previous reports mentioned that certain sialic acid bind-
ing residues from C. perfringens NanJ CBM (namely
Glu79 and Arg81) were conserved in closely related CBMs
from S. pneumoniae NanB and M. decora NanL but dif-
fered in NanA CBM. However, an alignment based on the
SpCBM structure reveals that these residues are, in fact,
conserved and correspond to NanA residues Glu195 and
Arg197. Other residues in the immediate area (Arg274
and Tyr182) are also conserved and form very similar
interactions as Arg151 and Tyr66 in NanJ. In S. pneumo-
niae NanB, residues corresponding to NanA Glu195,
Arg197, Arg274 and Tyr182 are conserved and adopt very
similar positions to that of NanA, suggesting that NanB is
likely to bind sialic acid in a similar manner.
The binding mode in the region of the glycerol moiety
is somewhat different in NanJ CBM and SpCBM. In
Fig. 5 Stereo view of Neu5Ac binding sites of SpCBM. 3’SL is shown in yellow carbon atoms and waters are shown in magenta. SpCBM residues
that are involved in the interaction are shown in stick representation with green carbon atoms. Hydrogen bonds are shown as black dotted lines
Table 1 Interactions between SpCBM and 3’SL. Intermolecular
hydrogen bonds between SpCBM and 3’SL are listed. Water
molecules bound to 3’SL are also detailed
3’SL Protein/Water atoms Distance (Å)
O-1 A Arg274-N-η2 2.88
O-1 A Arg197-N-η1 3.15
O-1 A H2O (W1) 2.74
O-1 B Arg274-N-η1 2.90
O-4 Glu195-O-ε1 2.71
O-4 Glu195-O-ε2 3.39
O-4 H2O (W3) 2.66
O-8 Trp280-N-ε1 2.87
O-8 H2O (W2) 3.15
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SpCBM, a hydrogen bond is formed between Trp280
and the C-7 hydroxyl, whereas the corresponding resi-
due in NanJ (Tyr158) cannot make this interaction,
instead forming a different H-bond to the glycerol group
via Asn156. The space filled by this Asn side chain,
along with the adjacent residue Tyr155, is not occupied
by any residues in the corresponding area of SpCBM or
NanB, creating a more open binding pocket in the
streptococcal proteins.
From binding affinity analysis, the dissociation constant,
KD for SpCBM-3’SL interaction was found to be in the af-
finity range similar to that measured for the isolated
CBM40 from V. cholerae NanH interacting with 3’SL
(1.8 μM) as determined by Surface Plasmon Resonance
(SPR) [21]. This suggests that the sialic acid binding
pocket of both CBM40s may be similar. On examination
of the residues involved in sialic acid binding by VcCBM
[20], both CBM40s involve a comparable number of direct
and water-mediated interactions that target the sialic acid
moiety alone, despite the overall topology of the binding
sites being different between them.
Besides the classic function of binding to sialic acid,
NanA was reported to enhance the S. pneumoniae inter-
action with human brain microvascular endothelial cells
(hBMECs) via an adhesin function of NanA-CBM, which
can potentially facilitate the entry of bacterial pathogens
Fig. 6 Potential functional cavity of SpCBM. a The surface electrostatic view from the top of the binding site of SpCBM and a cavity adjacent to
the active site, which is occupied by a lysine from a symmetry related molecule (shown in cyan). b Close-up view of the interaction between the
lysine and the protein. The solvent-accessible surface of SpCBM is coloured based on the electrostatic potential from −7 (red) to +7 (blue) kT/e,
calculated using the APBS tool in PyMOL [34, 35]
Fig. 7 Prediction of protein-protein interaction site. The SpCBM surface is coloured according to meta-PPISP score. Residues are coloured from
green (low propensity for protein binding) to red (high propensity). The sialic acid moiety of 3’SL is shown in stick representation with purple
carbon atoms
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into the central nervous system (CNS), even with little
contribution of the sialidase activity [10]. However, it is
still not completely clear which receptor in the hBMECs
is important for this process, and how it could be recog-
nized by NanA-CBM. In the current study, the surface
electrostatic view shows that there is a deep, negatively
charged cavity with positively charged surface next to
the sialic binding site (Fig. 6a), which is not present in
the other family 40 CBMs. Of the four amino acids that
form the cavity, only Glu195 is conserved, whereas
Gln203, Asn207 and Asn209 are present in a region of
sequence that exhibits low homology in family 40 CBMs,
suggesting that this surface feature is exclusive to S.
pneumoniae NanA. The four residues interact with a
lysine from a symmetry related molecule (Fig. 6b).
Therefore, it is possible that this region is important for
S. pneumoniae NanA CBM interaction with a host cell
receptor. This proposed interaction site for a binding
partner for NanA CBM is supported by the output of
the metaPPISP web server, which combines results from
three different methods for predicting protein-protein
interaction sites. The predicted region lies directly adja-
cent to the sialic acid binding site and the acidic pocket.
Conclusions
In summary, we have determined the structure of the
isolated form of CBM from S. pneumoniae NanA, which
has been identified as a Family 40 CBM due to its ability
to bind the terminal sialic acid of glycoconjugates. Our
findings suggest that this domain may enhance the
virulence of NanA by targeting and binding to a variety
of linkage-independent sialic acid receptors that line
the surface of respiratory epithelial cells. Further exper-
iments to determine the NanA binding partner(s) are
ongoing. The SpCBM domain, in addition to showing
promise as a bio-therapeutic against respiratory patho-
gens [12, 22], is a potential drug target and may be
exploited as part of a combinatorial drug design ap-
proach to inhibit NanA attachment and catalysis.
Methods
Cloning, expression, and purification
The gene encoding the SpCBM domain from S. pneumo-
niae NanA (UniProt: P62575) was generated by the
polymerase chain reaction (PCR) using the following
primers 5’-GGCTCCATGGTGATAGAAAAAGAAGAT
G-3’ and 5’-GCACTCGAGTCATTTAAAAAGTTGACT
ACG-3’ (NcoI and XhoI restriction sites in bold) and
pQE30 vector containing the nanA sialidase gene as
template. The PCR fragment was purified using a Gel
Extraction Kit (QIAGEN) prior to ligation into an
appropriately digested pEHISGFPTEV vector [23]. The
construct was propagated in Escherichia coli DH5α cells
with positive colonies identified by colony PCR. The
DNA sequence was confirmed by sequencing (The
Sequencing Service, University of Dundee, UK), prior to
transforming E. coli BL21 (DE3) expression strain
(Novagen) for protein production.
Expression of SpCBM was achieved by inoculating
Luria Broth (LB) medium containing 50 μg/ml kanamy-
cin with a single colony and incubating at 37 °C until
cultures reached an absorbance at 600 nm (A600) of 0.6.
Cultures were subjected to heat shock at 42 °C for
20 minutes prior to cooling to 25 °C and induced with
isopropyl thio-β-D-galactopyranoside (IPTG, 0.5 mM
final concentration) to induce expression of SpCBM.
Cultures were left to incubate further overnight at 18 °C
before harvesting by centrifugation at 10,000 g for 20 min.
Cell pellets were resuspended in phosphate-buffered saline
(PBS; 20 mM sodium phosphate, 150 mM sodium
Fig. 8 Bio-layer Interferometry. Association of SpCBM with 3’SL immobilized to a probe via a biotin linkage as measured using bio-layer interferometry.
a Sensogram showing the response units against increasing concentrations of SpCBM. b Steady-state binding of SpCBM-3’SL interaction determined by
plotting the response at equilibrium against SpCBM concentration and globally fitted using a 1:1 (Langmuir) binding model
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chloride, pH7.4) containing 10 mM imidazole and
300 mM sodium chloride with DNase I (Sigma, final con-
centration 20 μg/ml) and EDTA-free protease inhibitor
tablets (one tablet per 50 ml extract, Roche Diagnostics).
The cell suspension was lysed by sonication to disrupt
cells then subjected to centrifugation at 40,000 g for
30 min at 4 °C to remove cell debris. Clarified superna-
tants were collected and filtered with a 0.2 μm pore size
syringe-driven filter before further protein purification.
The soluble cell extract was initially loaded onto a
20 ml HisPrep FF 16/10 column (GE Healthcare) equili-
brated in PBS containing 10 mM imidazole and 300 mM
sodium chloride. The column was then washed with
PBS buffer containing 20 mM imidazole and 300 mM
NaCl before eluting bound protein using the PBS/NaCl
buffer supplemented with 250 mM imidazole. Eluted
fractions were then treated with TEV protease overnight
to remove the His-GFP tag. Cleaved proteins were fur-
ther purified by re-applying to the 20 ml HisPrep FF 16/
10 column. The collected flow through was concentrated
before performing size exclusion chromatography using
a HiPrep 26/60 Sephacryl S-200 HR column (GE Health-
care), which was pre-equilibrated in 20 mM sodium cit-
rate, pH6.0 containing 50 mM sodium chloride. Fractions
from the observed peaks were analyzed separately by
SDS-PAGE gel. Protein identity and integrity were con-
firmed by mass spectrometry (BSRC Mass Spectrometry
and Proteomics Facility, University of St Andrews).
Purified SpCBM was collected, concentrated and stored
at −80 °C for future use.
Bio-Layer Interferometry (BLI)
The binding affinity assay of SpCBM to 3’SL was
performed using the ForteBio Octet RED384 system
Table 2 Data collection and refinement statistics
Crystal Apo 3’SL complex 6’SL complex
Data collectiona
Space group and cell dimensions (Å,°) P21 P21 P21
a = 39.2, b = 67.0,
c = 66.8, β = 92.3
a = 42.6, b = 44.5,
c = 43.0, β = 97.0
a = 42.5, b = 44.6,
c = 43.0, β = 97.0
Resolution (Å) 67.0-1.8 44.5-1.8 44.6-1.8
Unique reflections 29,236 12,926 13,634
Completeness (%) 97 (74) 92 (76) 97 (83)
Redundancy 2.5 (2.0) 2.4 (1.7) 3.0 (2.2)
R-mergeb 0.031 (0.069) 0.069 (0.108) 0.049 (0.093)
I/σI 43.9 (22.7) 38.7 (16.8) 44.1 (16.8)
Refinement
Reflections used 27,743 12,277 12,950
Number of protein atoms 2,986 1,532 1,528
Number of ligand atoms - 43 43
Number of waters 403 166 148
R-factorc 0.163 0.143 0.150
R-freed 0.218 0.198 0.195
rmsd bond lengths (Å) 0.02 0.02 0.02
rmsd bond angles (°) 2.10 2.04 2.08
Average B-factors (Å2)
all atoms 16.3 15.2 15.9
ligand atoms - 27.8 32.4
waters 28.5 27.8 26.4
Molprobity score 1.80 1.20 1.40
Ramachandran favoured/outliers (%) 97/0 98/0 97/0
aNumbers in parentheses refer to the highest resolution shell
bR-merge = Σhkl Σi | Ihkl, i - < Ihkl > | / Σhkl < Ihkl>
cR-factor = (Σ | |Fo| - |Fc| |) / (Σ |Fo|)
dTest set comprised 5 % of reflections
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(ForteBio). Assays were performed in black 96 wells plates
(Nunc™ F96 MicroWell™ plate, Thermo Scientific) using
PBS containing 0.002 % Tween-20 as running buffer at
25 °C. Super streptavidin-coated (SSA) biosensor tips (For-
teBio) were pre-hydrated in 200 μl running buffer for
10 min followed by equilibration in PBS for 60 s. Tips
were non-covalently loaded with a 25 μg/ml solution of a
multivalent biotinylated 3’SL-polyacrylamide (Glycotech)
in running buffer for 300 s followed by a wash of 60 s in
the same buffer. All sensors, including reference sensors
(no ligand), were blocked with biocytin (Life Technolo-
gies) for 60 s, to prevent non-specific interactions of
protein to the sensor surface, followed by a further
wash for 60 s. Association of biotinylated ligand with
SpCBM (5-fold dilution series using a 10 μM stock in
running buffer) was performed for 150 s before dissoci-
ation of binding was performed using running buffer
for 150 s. All experiments were performed in triplicate.
Data were processed to calculate kinetic and affinity pa-
rameters using the ForteBio software.
Protein crystallization
Purified SpCBM was concentrated to 33 mg/ml based
on the results of precrystallization assay kit screening
(Hampton Research). All the subsequent crystallization
experiments were done at 20 °C by the sitting-drop,
vapour-diffusion method. Initially, commercial kits Crys-
tal Screen, SaltRx, Index (Hampton Research), Wizard,
Cryo I&II (Emerald BioSystems), JCSG Suite, PACT
Suite and PEGs Suite (Qiagen) were screened by a Hon-
eybee 963 robot system (Genomic Solutions) for protein
crystallization. Conditions with crystalline materials were
selected for crystallization optimization. After several
rounds of optimizations, the best crystals were obtained
in 120 mM MMT (molar ratios 1:2:2 of DL-malic acid:
MES: Tris Base) buffer pH9.0, 25 % (w/v) PEG1500.
Crystals appeared the next day and reached their max-
imum size within two weeks. Structures of complexes with
Neu5Ac derivatives were obtained by co-crystallization
with SpCBM. Protein solution (33 mg/ml) containing
5 mM ligand was incubated at 4 °C for 30 min followed by
mixing with an equal volume of reservoir solution
(100 mM MMT pH9.0 and 28 % (w/v) PEG1500). The
crystals appeared the next day and reached maximum size
in 3–4 days.
X-ray diffraction data collection and processing
Crystals were cryoprotected by transfer for a few seconds
to a solution of the crystallization buffer with 5 % (w/v)
ethylene glycol added before data collection at 100 K. All
X-ray diffraction data were collected in-house on a Rigaku
007HFM (Cu anode, λ = 1.54178) X-ray generator, with a
Saturn 944CCD detector. HKL2000 was used for data pro-
cessing and integration [24]. Apo SpCBM crystals belong
to the monoclinic space group P21, with two monomers in
an asymmetric unit. Crystals of complexes were also P21
but contained one monomer per asymmetric unit. Data
collection statistics are given in Table 2.
Structure determination and refinement
The leech trans-sialidase structure [PDB ID: 2SLI] was
used to solve the SpCBM structure by molecular replace-
ment with the PHASER program from the CCP4 suite
[25, 26]. Refinement was carried out with the program
REFMAC5 [27] from the CCP4 suite and the refined
model was manually adjusted in Coot [28]. After further
refinement with REFMAC5, the structures were inspected
and validated with Coot and MolProbity [29]. Refinement
statistics are summarized in Table 2.
Prediction of protein-protein interaction sites
The meta-PPISP server was used to predict potential
protein-protein interaction sites on SpCBM [30]. The
server combines three different methods in a linear
regression analysis, a strategy which improves accuracy
compared to the individual methods [31–33]. For com-
parison, the same analysis was carried out on the other
family 40 CBMs of known structure.
Availability of supporting data
Coordinates and structure factors have been deposited
in the Protein Data Bank with accession numbers 4ZXK,
4C1W and 4C1X for the apo structure, the 3’SL complex
and the 6’SL complex, respectively.
Abbreviations
NanA: Neuraminidase A; CBM: Carbohydrate-Binding Module;
SpCBM: Streptococcus pneumoniae NanA CBM; 3’SL: α2,3-sialyllactose;
6’SL: α2,6-sialyllactose; hBMECs: human brain microvascular endothelial cells;
BBB: Blood–brain-barrier; RMSD: Root Mean Square Deviation; SPR: Surface
Plasmon Resonance; BLI: Bio-Layer Interferometry.
Competing interests
HC and GLT are inventors on a patent held by the University of St Andrews
that includes the therapeutic use of SpCBM. LY and JAP declare that they
have no competing interests.
Authors’ contributions
GLT conceived and coordinated the study. HC, JAP and LY analyzed the
structural and affinity data, prepared figures and wrote the manuscript. HC
designed and produced the construct for SpNanA CBM expression. LY
expressed, purified, crystallized and determined the X-ray structures of
SpNanA CBM. All authors reviewed the results and approved the final version
of the manuscript.
Acknowledgements
This research was supported by the University of St Andrews and grants
provided by the Medical Research Council. We thank Dr David Robinson at
the University of Dundee for assistance in the collection and analysis of
Octet data.
Received: 2 July 2015 Accepted: 11 August 2015
Yang et al. BMC Structural Biology  (2015) 15:15 Page 9 of 10
References
1. Jedrzejas MJ. Pneumococcal virulence factors: structure and function.
Microbiology and molecular biology reviews : MMBR. 2001;65(2):187–207.
doi:10.1128/MMBR.65.2.187-207.2001. first page, table of contents.
2. Pettigrew MM, Fennie KP, York MP, Daniels J, Ghaffar F. Variation in the
presence of neuraminidase genes among Streptococcus pneumoniae
isolates with identical sequence types. Infect Immun. 2006;74(6):3360–5.
3. Manco S, Hernon F, Yesilkaya H, Paton JC, Andrew PW, Kadioglu A.
Pneumococcal neuraminidases A and B both have essential roles during
infection of the respiratory tract and sepsis. Infect Immun. 2006;74(7):4014–20.
doi:10.1128/IAI.01237-05.
4. Tong HH, Blue LE, James MA, DeMaria TF. Evaluation of the virulence of a
Streptococcus pneumoniae neuraminidase-deficient mutant in
nasopharyngeal colonization and development of otitis media in the
chinchilla model. Infect Immun. 2000;68(2):921–4.
5. Tong HH, Liu X, Chen Y, James M, Demaria T. Effect of neuraminidase on
receptor-mediated adherence of Streptococcus pneumoniae to chinchilla
tracheal epithelium. Acta Otolaryngol. 2002;122(4):413–9.
6. Parker D, Soong G, Planet P, Brower J, Ratner AJ, Prince A. The NanA
neuraminidase of Streptococcus pneumoniae is involved in biofilm
formation. Infect Immun. 2009;77(9):3722–30. doi:10.1128/IAI.00228-09.
7. Shakhnovich EA, King SJ, Weiser JN. Neuraminidase expressed by
Streptococcus pneumoniae desialylates the lipopolysaccharide of Neisseria
meningitidis and Haemophilus influenzae: a paradigm for interbacterial
competition among pathogens of the human respiratory tract. Infect
Immun. 2002;70(12):7161–4.
8. Chen GY, Chen X, King S, Cavassani KA, Cheng J, Zheng X, et al. Amelioration
of sepsis by inhibiting sialidase-mediated disruption of the CD24-SiglecG
interaction. Nat Biotechnol. 2011;29(5):428–35. doi:10.1038/nbt.1846.
9. King SJ, Whatmore AM, Dowson CG. NanA, a neuraminidase from
Streptococcus pneumoniae, shows high levels of sequence diversity, at least
in part through recombination with Streptococcus oralis. J Bacteriol.
2005;187(15):5376–86. doi:10.1128/JB.187.15.5376-5386.2005.
10. Uchiyama S, Carlin AF, Khosravi A, Weiman S, Banerjee A, Quach D, et al.
The surface-anchored NanA protein promotes pneumococcal brain
endothelial cell invasion. J Exp Med. 2009;206(9):1845–52. doi:10.1084/
jem.20090386.
11. Banerjee A, Van Sorge NM, Sheen TR, Uchiyama S, Mitchell TJ, Doran KS.
Activation of brain endothelium by pneumococcal neuraminidase NanA
promotes bacterial internalization. Cell Microbiol. 2010;12(11):1576–88.
doi:10.1111/j.1462-5822.2010.01490.x.
12. Connaris H, Govorkova EA, Ligertwood Y, Dutia BM, Yang L, Tauber S, et al.
Prevention of influenza by targeting host receptors using engineered
proteins. Proc Natl Acad Sci U S A. 2014;111(17):6401–6. doi:10.1073/
pnas.1404205111.
13. Cantarel BL, Coutinho PM, Rancurel C, Bernard T, Lombard V, Henrissat B.
The Carbohydrate-Active EnZymes database (CAZy): an expert resource for
Glycogenomics. Nucleic Acids Res. 2009;37(Database issue):D233–8.
doi:10.1093/nar/gkn663.
14. Xu G, Li X, Andrew PW, Taylor GL. Structure of the catalytic domain of
Streptococcus pneumoniae sialidase NanA. Acta Crystallogr, Sect F: Struct
Biol Cryst Commun. 2008;64(Pt 9):772–5. doi:10.1107/S1744309108024044.
15. Xu G, Kiefel MJ, Wilson JC, Andrew PW, Oggioni MR, Taylor GL. Three
Streptococcus pneumoniae Sialidases: Three Different Products. Journal of
the American Chemical Society. 2011. doi:10.1021/ja110733q.
16. Hsiao YS, Parker D, Ratner AJ, Prince A, Tong L. Crystal structures of
respiratory pathogen neuraminidases. Biochem Biophys Res Commun.
2009;380(3):467–71. doi:10.1016/j.bbrc.2009.01.108.
17. Boraston AB, Ficko-Blean E, Healey M. Carbohydrate recognition by a large
sialidase toxin from Clostridium perfringens. Biochemistry. 2007;46(40):11352–60.
doi:10.1021/bi701317g.
18. Xu G, Potter JA, Russell RJ, Oggioni MR, Andrew PW, Taylor GL. Crystal
structure of the NanB sialidase from Streptococcus pneumoniae. J Mol Biol.
2008;384(2):436–49. doi:10.1016/j.jmb.2008.09.032.
19. Luo Y, Li SC, Chou MY, Li YT, Luo M. The crystal structure of an
intramolecular trans-sialidase with a NeuAc alpha2–3Gal specificity.
Structure. 1998;6(4):521–30.
20. Moustafa I, Connaris H, Taylor M, Zaitsev V, Wilson JC, Kiefel MJ, et al. Sialic
acid recognition by Vibrio cholerae neuraminidase. J Biol Chem.
2004;279(39):40819–26. doi:10.1074/jbc.M404965200.
21. Connaris H, Crocker PR, Taylor GL. Enhancing the receptor affinity of the
sialic acid-binding domain of Vibrio cholerae sialidase through multivalency.
J Biol Chem. 2009;284(11):7339–51. doi:10.1074/jbc.M807398200.
22. Govorkova EA, Baranovich T, Marathe BM, Yang L, Taylor MA, Webster RG,
et al. Sialic acid-binding protein Sp2CBMTD protects mice against lethal
challenge with emerging influenza A (H7N9) virus. Antimicrob Agents
Chemother. 2015;59(3):1495–504. doi:10.1128/AAC.04431-14.
23. Liu H, Naismith JH. A simple and efficient expression and purification
system using two newly constructed vectors. Protein Expr Purif.
2009;63(2):102–11. doi:10.1016/j.pep.2008.09.008.
24. Otwinowski Z, Minor W. Processing of X-ray diffraction data collected in
oscillation mode. Method Enzymol. 1997;276:307–26.
25. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ.
Phaser crystallographic software. J Appl Crystallogr. 2007;40(Pt 4):658–74.
doi:10.1107/S0021889807021206.
26. Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, et al.
Overview of the CCP4 suite and current developments. Acta Crystallogr D
Biol Crystallogr. 2011;67(Pt 4):235–42. doi:10.1107/S0907444910045749.
27. Murshudov GN, Vagin AA, Dodson EJ. Refinement of macromolecular
structures by the maximum-likelihood method. Acta Crystallogr D Biol
Crystallogr. 1997;53(Pt 3):240–55. doi:10.1107/S0907444996012255.
28. Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of
Coot. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 4):486–501. doi:10.1107/
S0907444910007493.
29. Chen VB, Arendall 3rd WB, Headd JJ, Keedy DA, Immormino RM, Kapral GJ,
et al. MolProbity: all-atom structure validation for macromolecular
crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12–21.
doi:10.1107/S0907444909042073.
30. Qin S, Zhou HX. meta-PPISP: a meta web server for protein-protein
interaction site prediction. Bioinformatics. 2007;23(24):3386–7. doi:10.1093/
bioinformatics/btm434.
31. Chen H, Zhou HX. Prediction of interface residues in protein-protein
complexes by a consensus neural network method: test against NMR data.
Proteins. 2005;61(1):21–35. doi:10.1002/prot.20514.
32. Liang S, Zhang C, Liu S, Zhou Y. Protein binding site prediction using an
empirical scoring function. Nucleic Acids Res. 2006;34(13):3698–707.
doi:10.1093/nar/gkl454.
33. Neuvirth H, Raz R, Schreiber G. ProMate: a structure based prediction
program to identify the location of protein-protein binding sites. J Mol Biol.
2004;338(1):181–99. doi:10.1016/j.jmb.2004.02.040.
34. Baker NA, Sept D, Joseph S, Holst MJ, McCammon JA. Electrostatics of
nanosystems: application to microtubules and the ribosome. Proc Natl Acad
Sci U S A. 2001;98(18):10037–41. doi:10.1073/pnas.181342398.
35. Schrodinger L. The PyMOL Molecular Graphics System, Version 1.3r1. 2010.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Yang et al. BMC Structural Biology  (2015) 15:15 Page 10 of 10
